tiprankstipranks
Trending News
More News >

Senzime Secures New U.S. Patent for TetraGraph System

Story Highlights
  • Senzime AB focuses on neuromuscular monitoring solutions with its TetraGraph system.
  • A new U.S. patent enhances Senzime’s TetraGraph system, improving signal quality and competitive positioning.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Senzime Secures New U.S. Patent for TetraGraph System

Don’t Miss TipRanks’ Half-Year Sale

An announcement from Senzime AB ( (SE:SEZI) ) is now available.

Senzime AB has been granted a new U.S. patent for its TetraGraph system, which enhances the system’s capabilities by improving the quality of electromyography signals. This patent strengthens Senzime’s competitive position in the neuromuscular monitoring field, highlighting their commitment to innovation and patient safety.

More about Senzime AB

Senzime AB is a company operating in the medical technology industry, focusing on neuromuscular monitoring solutions. Their primary product, the TetraGraph system, is used in operating rooms to enhance patient safety by allowing precise dosing of neuromuscular blocking agents and ensuring safe recovery from anesthesia.

Average Trading Volume: 327,027

Current Market Cap: SEK799.8M

See more data about SEZI stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1